Regardless of commercialization plans, we do have the drug....

Regardless of commercialization plans, we do have the drug.

RC110 drug is currently being used - quite successfully - in Sheba 2, and the drug could be used again in follow up trials if requested.
The drug has a growing and historic safety and efficacy data.
The prevailing theory is that it should operate at least the same, and likely better, in the RC220 formulation.
If they discover that RC220 causes patients to grow a 12 foot tail, then they still have RC110.

I have really appreciated over the last few months the critical nature of a lot of comments, especially from the previously quite unrelentingly bullish users. This is a really healthy place to be and it shows a great intelligence in this community and puts the less scientifically educated like myself at ease. Management should be questioned - and it is spectacular that we get public and prompt answers to many questions.

But I would ask.. is the above comment not a bit nit picky? Has there not been enough detail provided about RC110 and RC220 for investors to come to their own understandings..